Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Read more
RINVOQ (upadacitinib) Approved by FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis Read more
GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics Read more
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions Read more
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors Read more
Pfizer and Biohaven’s VYDURA (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine Read more
ENHERTU Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer Read more
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity Read more